ArticleInternational journal of clinical and experimental medicine2015
Interleukin-10 promoter polymorphism and susceptibility to lung cancer: a systematic review and meta-analysis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 12 citations in OpenAlex.
- Sex Hormones and Lung Inflammation.Advances in experimental medicine and biology · 2021Article
- CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients.Frontiers in oncology · 2020Article
- Preliminary analysis of single-nucleotide polymorphisms in IL-10, IL-4, and IL-4Rα genes and profile of circulating cytokines in patients with gastric Cancer.BMC gastroenterology · 2018Article
- MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma.Oncotarget · 2016Article
- Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer.Disease markers · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterleukin-10 (IL-10) is a multifunctional cytokine with both immunosuppressive and anti-angiogenic properties and it plays an important role in the pathogenesis of cancer. A number of studies have examined the association between its promoter -1082/-819/-592 polymorphism and risk of lung cancer. However, the results are inconsistent and inconclusive. The aim of this study was to explore whether the IL-10 gene polymorphism contribute to the susceptibility of lung cancer.
methodWe searched in PubMed, EMBASE, Cochrane Library as well as Chinese databases including China National Knowledge Infrastructure (CNKI) and Wan Fang database for all the relevant studies up to May 15, 2015. The data were extracted by two independent authors. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) under co-dominant model, dominant model and recessive model were estimated.
resultsA total of 8 studies involving 2033 cases and 3100 controls were included in the meta-analysis. The results revealed that the IL-10 -592C/A polymorphism was related to lung cancer susceptibility under all models (C allele vs. A allele: OR=1.195, 95% CI=1.075-1.329; CC vs. AA: OR=1.651, 95%=1.290-2.113; CA vs. AA: OR=1.229, 95%=1.029-1.468; CA+AA vs. CC: OR=0.832, 95%=0.704-0.984; CC+CA vs. AA: OR=1.301, 95%=1.100-1.538) and IL-10 -819C/T polymorphism was associated with lung cancer susceptibility under three models (C allele vs. T allele: OR=1.441, 95% CI=1.228-1.691; CC vs. TT: OR=2.444, 95%=1.732-3.449; CC+CT vs. TT: OR=1.496, 95%=1.172-1.908). For IL-10 -1082G/A, there was no significant association between its polymorphism and lung cancer risk.
conclusionsThis meta-analysis demonstrated that two polymorphisms (-592C/A and -819C/T) in the promoter region of IL-10 gene were significantly associated with the risk of lung cancer in general population, while -1082G/A polymorphism did not affect susceptibility to lung cancer.
Indexed as
Identifiers
26629021PMC4658910W2410606153What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.